

Yu Qiao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11428908/publications.pdf>

Version: 2024-02-01

9
papers

436
citations

1040056

9
h-index

1474206

9
g-index

9
all docs

9
docs citations

9
times ranked

851
citing authors

#	ARTICLE	IF	CITATIONS
1	Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans. <i>Gut</i> , 2020, 69, 177-186.	12.1	121
2	Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice. <i>Oncogene</i> , 2018, 37, 3229-3242.	5.9	79
3	The mTORC2â€Akt1 Cascade Is Crucial for câ€Myc to Promote Hepatocarcinogenesis in Mice and Humans. <i>Hepatology</i> , 2019, 70, 1600-1613.	7.3	70
4	Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic Cholangiocarcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 403-413.	7.0	56
5	Tankyrase inhibitors suppress hepatocellular carcinoma cell growth via modulating the Hippo cascade. <i>PLoS ONE</i> , 2017, 12, e0184068.	2.5	35
6	Axis inhibition protein 1 (Axin1) Deletionâ€Induced Hepatocarcinogenesis Requires Intact Î²â€Catenin but Not Notch Cascade in Mice. <i>Hepatology</i> , 2019, 70, 2003-2017.	7.3	33
7	Functional role of SGK3 in PI3K/Pten driven liver tumor development. <i>BMC Cancer</i> , 2019, 19, 343.	2.6	17
8	Oncogene-dependent addiction to carbohydrate-responsive element binding protein in hepatocellular carcinoma. <i>Cell Cycle</i> , 2018, 17, 1496-1512.	2.6	14
9	Focal adhesion kinase activation limits efficacy of Dasatinib in câ€Myc driven hepatocellular carcinoma. <i>Cancer Medicine</i> , 2018, 7, 6170-6181.	2.8	11